Lithium succinate

Drug Profile

Lithium succinate

Alternative Names: Efadermin; Efalith

Latest Information Update: 24 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Louis Widmer; Scotia Holdings [CEASED]
  • Class Small molecules; Succinates
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Seborrhoeic dermatitis
  • Discontinued Atopic dermatitis; Human papillomavirus infections; Mycoses

Most Recent Events

  • 02 Apr 2015 The product is approved for Seborrhoeic dermatitis in EU countries and South Africa
  • 26 Jan 2012 Withdrawn for Seborrhoeic dermatitis in Ireland (Topical)
  • 22 Jan 2002 No-Development-Reported for Human papillomavirus infections in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top